Australia markets closed

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
21.50+0.33 (+1.54%)
As of 12:06PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 1.61B
Enterprise value 1.20B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.05
Enterprise value/revenue N/A
Enterprise value/EBITDA -8.01

Trading information

Stock price history

Beta (5Y monthly) 0.86
52-week change 378.50%
S&P500 52-week change 329.57%
52-week high 324.17
52-week low 37.41
50-day moving average 320.24
200-day moving average 312.89

Share statistics

Avg vol (3-month) 31.48M
Avg vol (10-day) 31.13M
Shares outstanding 576.14M
Implied shares outstanding 676.14M
Float 848.24M
% held by insiders 11.75%
% held by institutions 1105.54%
Shares short (15 Mar 2024) 410.3M
Short ratio (15 Mar 2024) 49.35
Short % of float (15 Mar 2024) 413.73%
Short % of shares outstanding (15 Mar 2024) 413.53%
Shares short (prior month 15 Feb 2024) 410.51M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-22.90%
Return on equity (ttm)-37.34%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -164.96M
Net income avi to common (ttm)-152.63M
Diluted EPS (ttm)-2.08
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)423.96M
Total cash per share (mrq)5.57
Total debt (mrq)17.2M
Total debt/equity (mrq)4.33%
Current ratio (mrq)12.26
Book value per share (mrq)5.34

Cash flow statement

Operating cash flow (ttm)-124.82M
Levered free cash flow (ttm)-63.9M